Why Is VERACYTE INC (VCYT) Stock Down Today?

Veracyte Inc (VCYT) fell 20.76% to $47.37 in a volatile session following a significant earnings report and mixed market reaction. The stock opened with a -9.7% gap down from the prior close and traded as low as $43.52 before settling at $47.38. The sharp decline came despite the company reporting strong second-quarter results, including 15% revenue growth and an updated 2026 revenue guidance range of $590M to $596M.

What Happened

Veracyte reported Q2 2026 results on July 30, 2026, with total revenue reaching $150.3 million, up 15% year-over-year. Testing revenue grew 19% to $145.7 million. The company also launched two new cancer tests, Prosigna and TrueMRD, and raised its 2026 revenue guidance. Despite these positive developments, the stock fell sharply in pre-market and continued to decline during the session. The earnings call highlighted risks and a reset in Decipher volume, which may have contributed to the sell-off. Additionally, the stock was upgraded by Freedom Capital, which raised its price target, but this did not prevent the drop.

What The Data Shows

The session saw heavy volume of 3.8 million shares, 3.4 times the 3-month daily average. The stock opened at $53.98 and hit a high of $54.25 before falling to a low of $43.52. Over the past 52 weeks, VCYT traded between $22.92 and $60.91. The stock has a market cap of $4.4 billion, a P/E ratio of 55.4, and a beta of 1.93. Recent insider transactions include seven sales totaling $9.7 million over the past 90 days, with no insider buys reported. Congressional trades show two buys but no sales in the same period.

What To Watch

Veracyte does not have an upcoming earnings date. Investors should monitor coverage breadth and market sentiment as the stock continues to trade near its 52-week low.